Table 3.
Factors associated with survival from date of diagnosis, date of blood draw for ctDNA test and from date of metastatic/recurrent disease (n = 433 patients)
| Variables | Univariate |
Multivariate1 |
|||
|---|---|---|---|---|---|
| Median OS (months) |
HR (95% CI) | p-value | HR (95% CI) | p-value | |
| OS from date of diagnosis | |||||
| Age | |||||
| ≥60 years (n = 199) vs. <60 years (n = 234) | 57.6 vs. 103.8 | 1.84 (1.40–2.43) | <0.001 | 1.99 (1.50–2.64) | <0.001 |
| Gender | |||||
| Women (n = 237) vs. men (n = 196) | 78.1 vs. 68.0 | 0.95 (0.72–1.24) | 0.69 | – | – |
| Type of cancer | |||||
| GI or HPB (n = 144) vs. not (n = 289) | 53.2 vs. 88.8 | 1.65 (1.24–2.18) | <0.001 | 1.47 (1.08–1.99) | 0.01 |
| Time interval between tissue biopsy and blood draw | |||||
| ≤6 months (n = 234) vs. >6 months (n = 199) | 65.1 vs. 85.1 | 1.41 (1.08–1.84) | 0.01 | 1.43 (1.09–1.88) | 0.009 |
| KRAS alteration seen in ctDNA and/or tissue DNA | |||||
| Yes (n = 101) vs. no (n = 332) | 73.5 vs. 78.1 | 1.21 (0.89–1.66) | 0.23 | – | – |
| KRAS alteration seen in both ctDNA and tissue DNA | |||||
| Yes (n = 36) vs. no (n = 397) | 32.2 vs. 78.1 | 1.98 (1.26–3.12) | 0.003 | 1.72 (1.04–2.86) | 0.04 |
| OS from date of blood draw for ctDNA test | |||||
| Age | |||||
| ≥60 years (n = 199) vs. <60 years (n = 234) | 13.7 vs. 21.8 | 1.34 (1.03–1.75) | 0.03 | 1.37 (1.05–1.80) | 0.02 |
| Gender | |||||
| Women (n = 237) vs. men (n = 196) | 18.0 vs. 21.8 | 1.05 (0.81–1.38) | 0.71 | – | – |
| Type of cancer | |||||
| GI or HPB (n = 144) vs. not (n = 289) | 13.3 vs. 18.8 | 1.31 (0.99–1.72) | 0.06 | 1.21 (0.90–1.62) | 0.21 |
| Time interval between tissue biopsy and blood draw | - | - | |||
| ≤6 months (n = 234) vs. >6 months (n = 199) | 17.2 vs. 18.8 | 1.07 (0.81–1.39) | 0.65 | ||
| KRAS alteration seen in ctDNA and/or tissue DNA | |||||
| Yes (n = 101) vs. no (n = 332) | 15.0 vs. 18.2 | 1.19 (0.87–1.63) | 0.27 | – | – |
| KRAS alteration seen in both ctDNA and tissue DNA | |||||
| Yes (n = 36) vs. not (n = 397) | 9.0 vs. 18.8 | 1.61 (1.03–2.53) | 0.04 | 1.52 (0.94–2.46) | 0.09 |
| OS from date of metastatic or recurrent disease2 | |||||
| Age | |||||
| ≥60 years (n = 185) vs. <60 years (n = 220) | 30.0 vs. 44.2 | 1.54 (1.18–2.02) | 0.001 | 1.66 (1.26–2.18) | <0.001 |
| Gender | |||||
| Women (n = 222) vs. men (n = 183) | 42.1 vs. 35.1 | 0.82 (0.63–1.08) | 0.16 | – | – |
| Type of cancer | |||||
| GI or HPB (n = 137) vs. not (n = 268) | 32.2 vs. 43.6 | 1.56 (1.18–2.06) | 0.002 | 1.45 (1.07–1.96) | 0.02 |
| Time interval between tissue biopsy and blood draw | |||||
| ≤6 months (n = 221) vs. >6 months (n = 184) | 34.9 vs. 43.4 | 1.46 (1.12–1.92) | 0.006 | 1.48 (1.13–1.94) | 0.005 |
| KRAS alteration seen in ctDNA and/or tissue DNA | |||||
| Yes (n = 97) vs. no (n = 308) | 35.5 vs. 40.7 | 1.19 (0.86–1.62) | 0.29 | – | – |
| KRAS alteration seen in both ctDNA and tissue DNA | |||||
| Yes (n = 36) vs. not (n = 369) | 25.9 vs. 41.7 | 1.98 (1.26–3.13) | 0.003 | 1.70 (1.03–2.81) | 0.04 |
The bold values represent the statistically significant p-values.
1
Values of p < 0.15 in univariate were selected for multivariate analysis.
2
A total of 28 patients were excluded from the latter analysis because their disease was surgically resected.
Abbreviations: CI, confidence interval; GI, gastrointestinal; HPB, hepatic/pancreatic/biliary; HR, hazard ratio; NGS, next-generation sequencing; OS, overall survival.